Get started
Author

Patrizia Froesch

Targeting RET in Patients With RET -Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry
2017 · Oliver Gautschi, Julie Milia, et al. · Journal of Clinical Oncology · 360
PDF
SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non–Small-Cell Lung Cancer—A Multicenter Single-Arm Phase II Trial
2021 · Sacha I. Rothschild, Alfred Zippelius, et al. · Journal of Clinical Oncology · 333
PDF
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial
2017 · Rafael Rosell, Urania Dafni, et al. · The Lancet Respiratory Medicine · 182
Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma
2018 · Yannis Metaxas, Gareth Rivalland, et al. · Journal of Thoracic Oncology · 98
Clinical Outcome of ALK -Positive Non–Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs)
2016 · Sabine Schmid, Oliver Gautschi, et al. · Journal of Thoracic Oncology · 78
PDF
Impact of 18F-FDG PET/CT in Staging Patients With Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
2020 · Francesco Martucci, Mariarosa Pascale, et al. · Frontiers in Medicine · 66
PDF
Low prevalence ofChlamydia psittaciin ocular adnexal lymphomas from Cuban patients
2006 · Elías Gracia, Patrizia Froesch, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 39
SAKK 16/14: Anti-PD-L1 antibody durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC)—A multicenter single-arm phase II trial.
2020 · Sacha Rothschild, Alfred Zippelius, et al. · Journal of Clinical Oncology · 37
Patterns of survival of follicular lymphomas at a single institution through three decades
2010 · Annarita Conconi, Maddalena Motta, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 36
Impact of the systematic introduction of low-cost bubble nasal CPAP in a NICU of a developing country: a prospective pre- and post-intervention study
2015 · Rossano Rezzonico, Letizia M Caccamo, et al. · BMC Pediatrics · 35
PDF
GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients
2020 · Nir Peled, Roni Gillis, et al. · Lung Cancer · 33
Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: A multicenter phase II trial (SAKK 19/05)
2012 · Francesco Zappa, Cornelia Droege, et al. · Lung Cancer · 32
Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16)
2020 · Y. Metaxas, M. Früh, et al. · Annals of Oncology · 31
PDF
Correlation of KRAS G12C Mutation and High PD-L1 Expression with Clinical Outcome in NSCLC Patients Treated with Anti-PD1 Immunotherapy
2022 · Marco Cefalì, Samantha Epistolio, et al. · Journal of Clinical Medicine · 28
PDF
Molecular Biology and Therapeutic Perspectives for K-Ras Mutant Non-Small Cell Lung Cancers
2022 · Elona Cekani, Samantha Epistolio, et al. · Cancers · 26
PDF
Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trial
2021 · Patrizia Froesch, Michael Mark, et al. · Lung Cancer · 21
SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2
2020 · Michael Mark, Patrizia Froesch, et al. · Cancer Immunology Immunotherapy · 16
Hodgkin and Non-Hodgkin Lymphomas During Pregnancy
2007 · Patrizia Froesch, Volmar Belisario-Filho, et al. · Springer eBooks · 15
Tumor immune dynamics and long-term clinical outcome of stage IIIA NSCLC patients treated with neoadjuvant chemoimmunotherapy
2025 · Dominic Schmid, Bettina Sobottka, et al. · Nature Communications · 14
PDF
SAKK 16/18: Immune-modulatory radiotherapy to enhance the effects of neoadjuvant PD-L1 blockade after neoadjuvant chemotherapy in patients with resectable stage III (N2) non-small cell lung cancer (NSCLC)—A multicenter phase II trial.
2023 · Laetitia A Mauti, Tobias Finazzi, et al. · Journal of Clinical Oncology · 14
PDF
1237MO SAKK 16/14: Anti-PD-L1 antibody durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA (N2) non-small cell lung cancer (NSCLC) – A multicenter single-arm phase II trial
2020 · S.I. Rothschild, A. Zippelius, et al. · Annals of Oncology · 12
PDF
First-Line Chemo-Immunotherapy in SCLC: Outcomes of a Binational Real-World Study
2024 · Laura Moliner, Núria Zellweger, et al. · JTO Clinical and Research Reports · 10
PDF
Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non–Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial
2016 · Oliver Gautschi, Sacha I. Rothschild, et al. · Clinical Lung Cancer · 10
Management of non-small cell lung cancer in the elderly
2014 · Patrizia Froesch, Francesco Martucci, et al. · European Journal of Internal Medicine · 10
PDF
Prognostic Impact of KRAS-TP53 Co-Mutations in Patients with Early-Stage Non-Small Cell Lung Cancer: A Single-Center Retrospective Study
2025 · Lucia Motta, Francesca Molinari, et al. · Journal of Clinical Medicine · 9
PDF
Works count: 80
Citation count: 1,605
H-index: 16
I10-index: 24
Year
Topic
Type